Shandong Jincheng Pharmaceutical Group (300233.SZ) announced that it recently signed a "Rights Licensing and Distribution Agreement" with Theramex HQ UK Limited, obtaining exclusive and proprietary commercialization rights for the estradiol and progesterone soft capsules (Bijuva) used for continuous combined hormone replacement therapy (HRT) for postmenopausal women's estrogen deficiency symptoms in China (including mainland China, Hong Kong, and Macau). This cooperation does not involve related-party transactions and does not constitute a major asset reorganization. The signing of the agreement is not expected to have a significant impact on the company's financial condition and operating performance for this fiscal year.
Shandong Jincheng Pharmaceutical Group: Signed a rights licensing and distribution agreement with Theramex.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Market Insights
Discussing
The tariff deferral period has been extended! How have trade policies in various countries evolved?
近日，美國總統特朗普表示「對等關稅」暫緩期從7月9日推遲至8月1日，並宣佈將從8月1日起對來自日本、韓國等14個國家的進口產品徵收25%-40%不等的關稅。7月12日，特朗普表示自8月1日起，將對墨西哥和歐盟徵收30%關稅。此前特朗普曾發文強調，8月1日起關稅將正式生效，再無延期
Food流油
Apr 14 15:43
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"